This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Shanghai Institutes for Biological Sciences, Cas. Active years: 2013.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2013
Title: The Innovations of Bing Luan
Introduction
Bing Luan is a notable inventor based in Shanghai, China. He has made significant contributions to the field of biomedical research, particularly in the area of insulin resistance. His work has implications for the diagnosis and treatment of related diseases, showcasing his commitment to advancing medical science.
Latest Patents
Bing Luan holds a patent titled "Methods and reagents for the diagnosis, prevention and treatment of insulin resistance using beta-arrestin2 and its up-regulators." This invention provides the use of β-arrestin2 protein or its up-regulators for manufacturing a composition aimed at preventing or treating insulin resistance or related diseases in mammals. The patent also includes reagents and kits for the specific identification of β-arrestin2 protein or its coding gene or transcript, which can be utilized in the diagnosis of insulin resistance or related diseases. He has 1 patent to his name.
Career Highlights
Bing Luan is affiliated with the Shanghai Institutes for Biological Sciences, where he conducts his research. His work is characterized by a strong focus on innovative solutions to complex health issues, particularly those related to metabolic disorders.
Collaborations
Bing Luan has collaborated with esteemed colleagues in his field, including Gang Pei and Jian Zhao. Their joint efforts contribute to the advancement of research and development in biomedical sciences.
Conclusion
Bing Luan's innovative work in the field of insulin resistance exemplifies the impact of dedicated research on health and medicine. His contributions are vital for the ongoing fight against metabolic diseases, and his patent reflects his commitment to improving patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile